Medical Facilities Corporation

Revenue was $63.1 million in Q2, up 7.8% year over year. Income from operations increased 9.4% to $9.6 million, and EBITDA rose 7.1% to $12.5 million. Operating expenses increased $3.8 million, or 7.6%; drugs and supplies were up 12.5%, salaries and benefits rose 6.4%, and G&A increased 3.8%. The company ended the quarter with $64.1 million of consolidated cash and $65.2 million of net working capital, compared with $43.4 million of cash and $54 million of net working capital at the end of December. Management did not provide formal next-quarter or full-year guidance on the call.

Jason Redman emphasized that the quarter reflected a favorable case mix, with more higher-value orthopedic and spine procedures driving stronger revenue and profitability. He also stressed capital returns, noting the company’s continued commitment to buybacks and that it has cumulatively returned approximately CAD 218 million to shareholders since the strategy shift in Q3 2022. His tone was constructive, highlighting liquidity and flexibility to support hospitals while evaluating further shareholder returns.

David Watson said the revenue increase came mainly from payer and case mix, with a smaller benefit from payer rate increases, while surgical case volume was down 2.3% and pain management cases fell 19.9%, largely due to Arkansas Surgical Hospital. He detailed expense pressure from higher drugs and supplies, salaries and benefits, and G&A, but still reported income from operations of $9.6 million and EBITDA of $12.5 million. He also pointed to a stronger balance sheet, with $64.1 million in cash, $65.2 million in net working capital, and no corporate-level bank debt after paying off the corporate credit facility in 2024.

There were no analyst questions in the queue, so no Q&A discussion occurred. As a result, management did not field follow-up questions on the pain-management weakness, the case-mix outlook, or future capital allocation beyond the prepared remarks.